查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2103866

纖維肌痛治療市場：全球市場預測，2026-2032年

Fibromyalgia Therapeutics Market - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 187 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，纖維肌痛治療市場將成長至 56.6 億美元，複合年成長率為 5.66%。

主要市場統計數據
基準年 2025 38.5億美元
預計年份：2026年 40.4億美元
預測年份 2032 56.6億美元
複合年成長率 (%) 5.66%

纖維肌痛症的治療重點在於改善慢性、廣泛性疼痛、疲勞、睡眠障礙、認知症狀、情緒相關合併症、與纖維肌痛相關的功能障礙。纖維肌痛症是一種複雜的中樞敏化疾病，已被國際臨床框架認可。整體情況包括已通過核准的藥物治療、臨床控制下的仿單標示外用藥、行為療法、運動療法、睡眠管理、病患教育以及多學科疼痛管理計畫。隨著臨床上越來越重視患者報告結果（PRO）、合併症篩檢和個人化治療路徑，人們對更安全、實證的纖維肌痛治療策略的需求日益成長。影響該領域的搜尋引擎最佳化（SEO）相關主題包括纖維肌痛治療、慢性疼痛管理、非鴉片類鎮痛、神經調控、數位療法、認知行為療法和個人化疼痛醫學。該領域也受到以下因素的影響：對鴉片類藥物處方的審查日益嚴格、對女性健康和疼痛護理公平性的認知不斷提高，以及將藥物治療和非藥物治療相結合的綜合護理模式的日益普及。

纖維肌痛治療的變革性變化

纖維肌痛的治療方法正從抑制症狀轉向以患者為中心的綜合疾病管理。臨床指引越來越強調教育、循序漸進的體能活動、認知行為療法、睡眠最佳化和選擇性藥物治療，而不是依賴單一干預措施。隨著醫療保健系統應對鴉片類藥物相關不利事件以及鴉片類藥物在纖維肌痛治療中作用有限等問題，非鴉片類鎮痛仍然是重中之重。疼痛神經科學的進展正在重新定義纖維肌痛，將其視為一種涉及中樞敏化、疼痛處理障礙、自主神經功能障礙以及伴隨的情緒和睡眠障礙的疾病，這推動了多方面治療流程。數位健康工具、遠端監測、基於遠端醫療的疼痛診所和基於應用程式的行為支援正在改善患者的護理連續性，這些患者往往面臨診斷延遲和治療碎片化的問題。同時，隨著保險公司和醫療保健提供者越來越關注實際療效、藥物依從性、耐受性和功能改善，人們越來越期望療法能夠對日常生活、睡眠品質、疲勞和工作參與產生有意義的影響。

人工智慧對纖維肌痛治療的累積影響

人工智慧 (AI) 正成為纖維肌痛治療的關鍵驅動力，它能夠支援早期檢測、個人化護理計劃和更有效率的臨床研究。 AI 驅動的分析技術可以透過分析電子健康記錄、患者報告結局 (PRO)、穿戴式感測器數據和數位疼痛日記，幫助識別症狀叢集、合併症模式、藥物反應徵兆以及治療依從性差的風險因素。在臨床開發中，機器學習能夠最佳化試驗設計，例如完善合格標準、降低異質性、支持分散式數據收集以及識別纖維肌痛這種以症狀表現多樣而聞名的疾病中的應答者亞組。在醫療保健領域，AI 驅動的決策工具可以幫助臨床醫生為患者制定合適的治療方案，這些方案結合了藥物治療、認知行為療法、睡眠干預、體育鍛煉提案、康復和心理健康支持。然而，負責任地使用 AI 需要透明的演算法、在不同人群中的檢驗、隱私保護以及避免疼痛評估中的偏見。特別是，慢性疼痛疾病的診斷和治療歷來受到性別、社會經濟地位和種族差異的影響。

關於纖維肌痛治療的關鍵區域性見解

在亞太地區，隨著都市區醫療體系對慢性疼痛疾病的認知不斷提高，纖維肌痛的治療也日益受到關注，尤其是在中國、日本、印度、韓國和澳洲。這一區域趨勢的形成受到多種因素的影響，包括診斷率的差異、風濕病和疼痛醫學體系的擴展、與精神衛生保健整合的進步，以及遠距遠端醫療和數位化症狀管理在彌合醫療保健差距方面的應用日益廣泛。北美地區在纖維肌痛治療創新方面仍然非常活躍，這得益於其較高的臨床認知度、多學科疼痛管理計畫的廣泛應用、強大的患者權益倡導以及持續向非鴉片類藥物慢性疼痛治療​​的轉變。在拉丁美洲，儘管巴西和墨西哥等主要經濟體的專科醫生資源正在不斷擴展和完善，但診斷不足、公共保險報銷政策的差異以及行為療法的可及性差距仍然影響著治療的可及性。歐洲的優勢在於其健全的臨床指引框架、跨境研究合作、藥物安全監測系統，以及藥物治療與物理治療、心理介入和睡眠管理的整合。在中東，隨著專業醫療基礎設施的擴展，需求不斷成長，海灣國家的醫療保健系統也更加重視慢性病管理、復健服務和數位醫療。在非洲，面臨著許多挑戰，例如專科醫生短缺、公眾意識薄弱以及與其他醫療保健挑戰的競爭，但透過遠端醫療、基層醫療培訓和提高對慢性疼痛症候群的認知，改善纖維肌痛治療的機會正在逐步湧現。

關於纖維肌痛治療的關鍵小組見解

在東南亞國協，隨著都市區醫院網路的擴張、疼痛醫學意識的提高以及行動醫療工具的廣泛應用，纖維肌痛的治療可及性正在改善；然而，確保不同醫療體系間診斷的一致性仍然是一項挑戰。海灣合作理事會（GCC）國家擁有先進的醫療基礎設施、對專科診所的投入增加以及數位醫療的日益普及，這些都為整合慢性疼痛管理和以康復主導的治療方法提供了支持。在歐盟，透過基於指南的實踐、藥物安全監測標準、衛生技術評估以及優先考慮患者安全和功能性結果的多學科協作護理模式，已建立了一套系統的纖維肌痛護理體系。金磚國家擁有龐大的患者群體，藥物可及性不斷擴大，數位醫療生態系統也在不斷發展，公共衛生部門對慢性非傳染性疾病的關注度也在提高，但報銷制度和專科醫生資源的差異影響了治療的可及性，從而形成了既多元又具有影響力的治療環境。七國集團（G7）國家通常具有以下特徵：積極的研究、完善的法律規範體系、廣泛的行為療法和復健服務，以及對非鴉片類止痛藥物的重視。北約成員國（其中許多與歐洲和北美重疊）擁有先進的臨床基礎設施和研究合作，支持證據生成、採用數位護理以及在更安全的慢性疼痛治療​​方面達成政策一致。

各國對纖維肌痛治療的重點見解

美國是纖維肌痛治療的主要中心，這得益於其對慢性疼痛的高度重視、已獲已通過核准和未獲仿單標示外療法的廣泛應用、遠端保健的高普及率、患者權益倡導以及旨在減少不當鴉片類藥物依賴的政策壓力。在加拿大，多學科疼痛治療、與心理健康的整合以及基於指南的治療方法備受重視，但各省獲得專業疼痛治療服務的機會不盡相同。墨西哥和巴西正透過擴大私人醫療保健的覆蓋範圍、建立專科網路以及開展慢性疼痛宣傳活動來提高人們對纖維肌痛的認知，但公共醫療保健領域的局限性和診斷不足仍然影響著治療路徑。在英國，實證非藥物療法、疼痛教育和基層醫療主導的管理得到了支持，而德國和法國則充分利用了其完善的醫療保健系統、風濕病學專業知識、系統化的保險報銷機制和全面的康復體系。在俄羅斯、義大利和西班牙，風濕病學和疼痛醫學領域對纖維肌痛的認知正在不斷提高，康復、睡眠護理、心理健康支持和適當的藥物治療仍然至關重要。中國正透過醫院現代化、數位醫療的普及以及對慢性疼痛疾病認知的提高而取得進展，而印度則面臨著雙重挑戰：都市區的診斷率不斷上升，但資源匱乏地區在醫療保健方面仍然存在持續的差距。在日本，人口老化、完善的臨床基礎設施以及對生活品質的關注正在塑造纖維肌痛的管理模式。同時，澳洲在成熟的多學科疼痛管理計畫、與基層醫療的整合以及數位醫療的應用方面取得了進展。韓國憑藉其先進的醫療技術、較高的數位醫療普及率和不斷擴展的疼痛管理服務，已成為病患監測、遠端醫療和個人化慢性疼痛護理領域創新的重要中心。

為行業領導者提供的實用建議

產業領導者應優先考慮能夠解決纖維肌痛症狀所有方面負擔的療法和護理模式，包括疼痛、疲勞、睡眠障礙、認知障礙、情緒症狀和身體功能障礙。研發項目應納入檢驗的患者報告結局（PRO）、真實世界數據（RWE）和亞組分析，以識別最有可能從特定乾預措施中獲益的患者。相關人員應投資於符合臨床指引和保險公司期望的非鴉片類藥物療法、聯合治療路徑、數位療法、遠端監測和藥物依從性支援工具。與臨床醫生、患者團體、學術機構和數位醫療服務提供者的合作可以改善教育、診斷和護理的連續性。醫療創新者也應設計全面的研究方案，考慮性別、年齡、種族、合併症和社會經濟差異對疼痛體驗的影響。監管和報銷策略不應僅關注降低疼痛評分，而應關注功能、睡眠、耐受性、安全性和生活品質方面的可衡量改善。

調查方法

本執行摘要基於檢驗的醫學、監管和公共衛生資源為中心的二手研究方法，包括同行評審的臨床文獻、國際疾病分類出版刊物、臨床實踐指南、藥物安全監測資訊來源、衛生機構出版物以及慢性疼痛治療​​的真實世界證據。研究途徑調查方法強調對臨床研究、指引說明、地方醫療政策指標、數位醫療應用趨勢和慢性疼痛管理標準等數據檢驗驗證。研究結果從纖維肌痛治療、非鴉片類藥物疼痛管理、多學科診療、人工智慧 (AI) 應用和區域可及性等方面進行了評估。本分析有意排除市場規模估算、市場規模計算、市場佔有率及市場預測。它整合了國家、區域和群體層面的觀點，在堅持循證解讀的同時，避免未經證實的商業性聲明，並提供說明見解以支持策略理解。

結論

纖維肌痛的治療正邁入一個更加整合、主導的時代，這一時代受到疼痛神經科學、非鴉片類藥物療法優先發展、數位醫療普及以及人工智慧日益廣泛的應用的影響。最永續的策略是將安全的藥物治療方案與行為療法、運動、睡眠管理、心理健康支持、康復以及持續的患者參與相結合。儘管診斷、保險報銷、專科醫生診療以及數位基礎設施方面的區域差異仍將影響治療方案的實施，但全球的通用包括早期發現、個人化護理以及功能和生活品質的可衡量改善。投資於以患者為中心的實證醫學、綜合研究、負責任的人工智慧以及多學科診療模式的行業相關人員將更有能力滿足纖維肌痛患者未被滿足的需求。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章 纖維肌痛治療市場：依藥物類別分類

  • 抗驚厥藥物
    • 品牌
    • 非專利的
  • 選擇性血清素再回收抑制劑
    • 品牌
    • 非專利的
  • 正腎上腺素再回收抑制劑
    • 品牌
    • 非專利的
  • 三環抗憂鬱藥物
    • 品牌
    • 非專利的

第8章 纖維肌痛治療市場：依給藥途徑分類

  • 口服
  • 腸外
  • 外用

第9章：纖維肌痛治療市場：依通路分類

  • 線上
  • 離線

第10章 纖維肌痛治療市場：依最終使用者分類

  • 居家照護
  • 醫院
  • 專科診所

第11章 纖維肌痛治療市場：依地區分類

  • 亞太地區
  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 中東
  • 非洲

第12章 纖維肌痛治療市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第13章 纖維肌痛治療市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第14章 競爭格局

  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第15章：公司簡介

  • AbbVie Inc.
  • Amgen Inc.
  • Amicus Therapeutics, Inc.
  • Astellas Pharma Inc.
  • AstraZeneca PLC
  • Bayer AG
  • Biogen Inc.
  • BioMarin Pharmaceutical Inc.
  • Bristol-Myers Squibb Company
  • CH Boehringer Sohn AG & Co. KG
  • Eli Lilly and Company
  • Gilead Sciences, Inc.
  • GSK plc
  • Jazz Pharmaceuticals plc
  • Johnson & Johnson
  • Kyowa Kirin Co., Ltd.
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • Regeneron Pharmaceuticals, Inc.
  • Roche Holding AG
  • Sanofi
  • Sarepta Therapeutics, Inc.
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd.
  • Vertex Pharmaceuticals Incorporated
  • Viatris Inc.
Product Code: MRR-8E22B61932B5

The Fibromyalgia Therapeutics Market is projected to grow by USD 5.66 billion at a CAGR of 5.66% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 3.85 billion
Estimated Year [2026] USD 4.04 billion
Forecast Year [2032] USD 5.66 billion
CAGR (%) 5.66%

Fibromyalgia therapeutics focus on improving chronic widespread pain, fatigue, sleep disturbance, cognitive symptoms, mood-related comorbidities, and functional impairment associated with fibromyalgia, a complex central sensitization condition recognized in international clinical frameworks. The therapeutic landscape includes approved pharmacologic options, clinically supervised off-label medicines, behavioral interventions, exercise-based care, sleep management, patient education, and multidisciplinary pain programs. Growing clinical attention to patient-reported outcomes, comorbidity screening, and individualized treatment pathways is strengthening demand for safer, evidence-based fibromyalgia treatment strategies. SEO-relevant themes shaping the field include fibromyalgia drugs, chronic pain therapeutics, non-opioid pain management, neuromodulation, digital therapeutics, cognitive behavioral therapy, and personalized pain medicine. The sector is also influenced by tighter scrutiny of opioid prescribing, increasing recognition of women's health and pain equity, and rising adoption of integrated care models that combine pharmacological and non-pharmacological approaches.

Transformative Shifts in Fibromyalgia Therapeutics

The fibromyalgia therapeutics landscape is shifting from symptom suppression toward integrated, patient-centered disease management. Clinical guidance increasingly emphasizes education, graded physical activity, cognitive behavioral approaches, sleep optimization, and selective pharmacotherapy rather than reliance on a single intervention. Non-opioid pain management remains a defining priority as health systems respond to opioid-related harms and the limited role of opioids in fibromyalgia care. Advances in pain neuroscience are reframing fibromyalgia as a disorder involving central sensitization, altered pain processing, autonomic dysregulation, and overlapping mood and sleep disorders, which is encouraging multimodal treatment algorithms. Digital health tools, remote monitoring, telehealth-enabled pain clinics, and app-based behavioral support are improving continuity of care for patients who often experience delayed diagnosis and fragmented treatment. At the same time, payer and provider focus on real-world outcomes, adherence, tolerability, and functional improvement is raising expectations for therapies that demonstrate meaningful benefits in daily living, sleep quality, fatigue, and work participation.

Cumulative Impact of AI on Fibromyalgia Therapeutics

Artificial intelligence is becoming an important enabler in fibromyalgia therapeutics by supporting earlier recognition, individualized care planning, and more efficient clinical research. AI-enabled analytics can help identify symptom clusters, comorbidity patterns, medication response signals, and risk factors for poor treatment adherence by analyzing electronic health records, patient-reported outcomes, wearable sensor data, and digital pain diaries. In clinical development, machine learning can improve trial design by refining eligibility criteria, reducing heterogeneity, supporting decentralized data collection, and detecting responder subgroups within a condition known for variable symptom expression. In care delivery, AI-supported decision tools may assist clinicians in matching patients with appropriate combinations of pharmacologic treatment, cognitive behavioral therapy, sleep interventions, physical activity plans, rehabilitation, and mental health support. However, responsible use requires transparent algorithms, validation across diverse populations, privacy safeguards, and avoidance of bias in pain assessment, particularly because chronic pain conditions have historically been affected by gender, socioeconomic, and racial disparities in recognition and treatment.

Key Regional Insights for Fibromyalgia Therapeutics

Asia-Pacific is witnessing rising attention to fibromyalgia therapeutics as awareness of chronic pain disorders improves across urban health systems, particularly in China, Japan, India, South Korea, and Australia. Regional dynamics are shaped by uneven diagnosis rates, expanding rheumatology and pain medicine capacity, growing mental health integration, and increasing use of telehealth and digital symptom management to address access gaps. North America remains a highly active region for fibromyalgia treatment innovation due to established clinical recognition, broad use of multidisciplinary pain programs, strong patient advocacy, and continued movement toward non-opioid chronic pain care. Latin America is advancing through expanding specialist access in larger economies such as Brazil and Mexico, although underdiagnosis, uneven public reimbursement, and variability in access to behavioral care continue to influence treatment adoption. Europe benefits from strong clinical guideline frameworks, cross-border research collaboration, pharmacovigilance systems, and increasing integration of pharmacological care with physiotherapy, psychological interventions, and sleep management. The Middle East is seeing demand rise alongside expanding specialty care infrastructure, with Gulf health systems placing greater emphasis on chronic disease management, rehabilitation services, and digital healthcare. Africa faces significant barriers, including limited specialist availability, low public awareness, and competing health priorities, yet telemedicine, primary care training, and greater recognition of chronic pain syndromes are creating gradual opportunities for improved fibromyalgia care.

Key Group Insights for Fibromyalgia Therapeutics

ASEAN countries are developing fibromyalgia therapeutics access through expanding urban hospital networks, improving pain medicine awareness, and growing use of mobile health tools, though diagnostic consistency remains a challenge across diverse healthcare systems. The GCC is positioned around advanced healthcare infrastructure, rising investment in specialty clinics, and increasing digital health adoption, which supports integrated chronic pain management and rehabilitation-led approaches. The European Union provides a structured environment for fibromyalgia care through guideline-driven practice, pharmacovigilance standards, health technology assessment, and multidisciplinary care models that prioritize patient safety and functional outcomes. BRICS countries reflect a mixed but influential therapeutic environment, with large patient populations, expanding pharmaceutical access, growing digital health ecosystems, and increasing public health focus on chronic noncommunicable conditions, while variability in reimbursement and specialist availability affects uptake. G7 countries generally show stronger research intensity, established regulatory oversight, broader access to behavioral and rehabilitative services, and greater emphasis on non-opioid pain management. NATO member countries, many of which overlap with Europe and North America, demonstrate advanced clinical infrastructure and research collaboration capacity, supporting evidence generation, digital care adoption, and policy alignment around safer chronic pain treatment.

Key Country Insights for Fibromyalgia Therapeutics

The United States is a major center for fibromyalgia therapeutics due to high chronic pain awareness, established use of approved and off-label therapies, strong telehealth penetration, patient advocacy, and policy pressure to reduce inappropriate opioid reliance. Canada emphasizes multidisciplinary pain care, mental health integration, and guideline-informed approaches, although access to specialized pain services varies by province. Mexico and Brazil are strengthening fibromyalgia recognition through expanding private healthcare access, specialist networks, and chronic pain education, while public-sector constraints and underdiagnosis continue to affect care pathways. The United Kingdom supports evidence-based non-pharmacological intervention, pain education, and primary care-led management, while Germany and France benefit from robust healthcare systems, rheumatology expertise, structured reimbursement environments, and strong rehabilitation capacity. Russia, Italy, and Spain show increasing recognition of fibromyalgia within rheumatology and pain medicine, with ongoing emphasis on rehabilitation, sleep care, mental health support, and appropriate pharmacotherapy. China is advancing through hospital modernization, digital health scale, and growing awareness of chronic pain disorders, while India faces a dual environment of rising diagnosis in urban centers and persistent access gaps in lower-resource settings. Japan's aging population, strong clinical infrastructure, and focus on quality-of-life outcomes shape fibromyalgia management, while Australia demonstrates mature multidisciplinary pain programs, primary care coordination, and digital health adoption. South Korea combines advanced healthcare technology, high digital engagement, and expanding pain management services, making it an important country for innovation in patient monitoring, telemedicine, and personalized chronic pain care.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize therapies and care models that address the full fibromyalgia symptom burden, including pain, fatigue, sleep disruption, cognitive dysfunction, mood symptoms, and reduced physical function. Development programs should incorporate validated patient-reported outcomes, real-world evidence, and subgroup analyses to identify patients most likely to benefit from specific interventions. Stakeholders should invest in non-opioid mechanisms, combination care pathways, digital therapeutics, remote monitoring, and adherence support tools that align with clinical guidelines and payer expectations. Partnerships with clinicians, patient organizations, academic groups, and digital health providers can improve education, diagnosis, and continuity of care. Healthcare innovators should also design inclusive research protocols that account for sex, age, ethnicity, comorbidities, and socioeconomic differences in pain experience. Regulatory and reimbursement strategies should emphasize measurable improvements in function, sleep, tolerability, safety, and quality of life rather than narrow pain-score reduction alone.

Research Methodology

This executive summary is developed using a secondary research approach centered on verified medical, regulatory, and public health sources, including peer-reviewed clinical literature, international disease classification references, clinical practice guidelines, pharmacovigilance resources, health agency publications, and real-world chronic pain care evidence. The methodology emphasizes data triangulation across clinical research, guideline statements, regional healthcare policy indicators, digital health adoption trends, and chronic pain management standards. Insights were evaluated for relevance to fibromyalgia therapeutics, non-opioid pain management, multidisciplinary care, artificial intelligence applications, and regional access dynamics. The analysis deliberately excludes market estimation, market sizing, market share, and market forecasting. Country, regional, and group-level perspectives were synthesized into narrative insights to support strategic understanding while maintaining evidence-based interpretation and avoiding unsupported commercial claims.

Conclusion

Fibromyalgia therapeutics are entering a more integrated, evidence-driven era shaped by pain neuroscience, non-opioid treatment priorities, digital health adoption, and growing use of artificial intelligence. The most resilient strategies will combine safe pharmacological options with behavioral therapy, exercise, sleep management, mental health support, rehabilitation, and continuous patient engagement. Regional differences in diagnosis, reimbursement, specialist access, and digital infrastructure will continue to influence adoption, while common global priorities include earlier recognition, personalized care, and measurable improvements in function and quality of life. Industry participants that invest in patient-centered evidence, inclusive research, responsible AI, and multidisciplinary delivery models will be best positioned to address the unmet needs of people living with fibromyalgia.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. New Revenue Opportunities
  • 3.5. Next-Generation Business Models
  • 3.6. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Fibromyalgia Therapeutics Market, by Drug Class

  • 7.1. Introduction
  • 7.2. Anticonvulsants
    • 7.2.1. Branded
    • 7.2.2. Generic
  • 7.3. Selective Serotonin Reuptake Inhibitors
    • 7.3.1. Branded
    • 7.3.2. Generic
  • 7.4. Serotonin And Norepinephrine Reuptake Inhibitors
    • 7.4.1. Branded
    • 7.4.2. Generic
  • 7.5. Tricyclic Antidepressants
    • 7.5.1. Branded
    • 7.5.2. Generic

8. Fibromyalgia Therapeutics Market, by Route Of Administration

  • 8.1. Introduction
  • 8.2. Oral
  • 8.3. Parenteral
  • 8.4. Topical

9. Fibromyalgia Therapeutics Market, by Distribution Channel

  • 9.1. Introduction
  • 9.2. Online
  • 9.3. Offline

10. Fibromyalgia Therapeutics Market, by End User

  • 10.1. Introduction
  • 10.2. Home Care
  • 10.3. Hospital
  • 10.4. Specialty Clinics

11. Fibromyalgia Therapeutics Market, by Region

  • 11.1. Asia-Pacific
  • 11.2. North America
  • 11.3. Latin America
  • 11.4. Europe
  • 11.5. Middle East
  • 11.6. Africa

12. Fibromyalgia Therapeutics Market, by Group

  • 12.1. ASEAN
  • 12.2. GCC
  • 12.3. European Union
  • 12.4. BRICS
  • 12.5. G7
  • 12.6. NATO

13. Fibromyalgia Therapeutics Market, by Country

  • 13.1. United States
  • 13.2. Canada
  • 13.3. Mexico
  • 13.4. Brazil
  • 13.5. United Kingdom
  • 13.6. Germany
  • 13.7. France
  • 13.8. Russia
  • 13.9. Italy
  • 13.10. Spain
  • 13.11. China
  • 13.12. India
  • 13.13. Japan
  • 13.14. Australia
  • 13.15. South Korea

14. Competitive Landscape

  • 14.1. Market Share Analysis, 2025
  • 14.2. FPNV Positioning Matrix, 2025
  • 14.3. Market Concentration Analysis, 2025
    • 14.3.1. Concentration Ratio (CR)
    • 14.3.2. Herfindahl Hirschman Index (HHI)
  • 14.4. Recent Developments & Impact Analysis, 2025
  • 14.5. Product Portfolio Analysis, 2025
  • 14.6. Benchmarking Analysis, 2025

15. Company Profiles

  • 15.1. AbbVie Inc.
  • 15.2. Amgen Inc.
  • 15.3. Amicus Therapeutics, Inc.
  • 15.4. Astellas Pharma Inc.
  • 15.5. AstraZeneca PLC
  • 15.6. Bayer AG
  • 15.7. Biogen Inc.
  • 15.8. BioMarin Pharmaceutical Inc.
  • 15.9. Bristol-Myers Squibb Company
  • 15.10. C. H. Boehringer Sohn AG & Co. KG
  • 15.11. Eli Lilly and Company
  • 15.12. Gilead Sciences, Inc.
  • 15.13. GSK plc
  • 15.14. Jazz Pharmaceuticals plc
  • 15.15. Johnson & Johnson
  • 15.16. Kyowa Kirin Co., Ltd.
  • 15.17. Merck & Co., Inc.
  • 15.18. Novartis AG
  • 15.19. Pfizer Inc.
  • 15.20. Regeneron Pharmaceuticals, Inc.
  • 15.21. Roche Holding AG
  • 15.22. Sanofi
  • 15.23. Sarepta Therapeutics, Inc.
  • 15.24. Takeda Pharmaceutical Company Limited
  • 15.25. Teva Pharmaceutical Industries Ltd.
  • 15.26. Vertex Pharmaceuticals Incorporated
  • 15.27. Viatris Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025 VS 2032 (%)
  • FIGURE 7. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY END USER, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 21. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025

LIST OF TABLES

  • TABLE 1. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL ANTICONVULSANTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL ANTICONVULSANTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL ANTICONVULSANTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL BRANDED MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL BRANDED MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL BRANDED MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL GENERIC MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL GENERIC MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL GENERIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL SELECTIVE SEROTONIN REUPTAKE INHIBITORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL SELECTIVE SEROTONIN REUPTAKE INHIBITORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL SELECTIVE SEROTONIN REUPTAKE INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL BRANDED MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL BRANDED MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL BRANDED MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL GENERIC MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL GENERIC MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL GENERIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL SEROTONIN AND NOREPINEPHRINE REUPTAKE INHIBITORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL SEROTONIN AND NOREPINEPHRINE REUPTAKE INHIBITORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL SEROTONIN AND NOREPINEPHRINE REUPTAKE INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL BRANDED MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL BRANDED MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL BRANDED MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL GENERIC MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL GENERIC MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL GENERIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL TRICYCLIC ANTIDEPRESSANTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL TRICYCLIC ANTIDEPRESSANTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL TRICYCLIC ANTIDEPRESSANTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL BRANDED MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL BRANDED MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL BRANDED MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL GENERIC MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL GENERIC MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL GENERIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL ORAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL ORAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL ORAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL PARENTERAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL PARENTERAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL PARENTERAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL TOPICAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL TOPICAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL TOPICAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL ONLINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL ONLINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL ONLINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL OFFLINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL OFFLINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL OFFLINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL HOME CARE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL HOME CARE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL HOME CARE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL HOSPITAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL HOSPITAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL HOSPITAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. ASIA-PACIFIC FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. ASIA-PACIFIC FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 70. ASIA-PACIFIC FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY ANTICONVULSANTS, 2018-2032 (USD MILLION)
  • TABLE 71. ASIA-PACIFIC FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 72. ASIA-PACIFIC FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY SEROTONIN AND NOREPINEPHRINE REUPTAKE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 73. ASIA-PACIFIC FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY TRICYCLIC ANTIDEPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 74. ASIA-PACIFIC FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 75. ASIA-PACIFIC FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 76. ASIA-PACIFIC FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 77. NORTH AMERICA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. NORTH AMERICA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 79. NORTH AMERICA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY ANTICONVULSANTS, 2018-2032 (USD MILLION)
  • TABLE 80. NORTH AMERICA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 81. NORTH AMERICA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY SEROTONIN AND NOREPINEPHRINE REUPTAKE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 82. NORTH AMERICA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY TRICYCLIC ANTIDEPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 83. NORTH AMERICA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 84. NORTH AMERICA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 85. NORTH AMERICA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 86. LATIN AMERICA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 87. LATIN AMERICA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 88. LATIN AMERICA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY ANTICONVULSANTS, 2018-2032 (USD MILLION)
  • TABLE 89. LATIN AMERICA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 90. LATIN AMERICA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY SEROTONIN AND NOREPINEPHRINE REUPTAKE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 91. LATIN AMERICA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY TRICYCLIC ANTIDEPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 92. LATIN AMERICA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 93. LATIN AMERICA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 94. LATIN AMERICA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 95. EUROPE FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 96. EUROPE FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 97. EUROPE FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY ANTICONVULSANTS, 2018-2032 (USD MILLION)
  • TABLE 98. EUROPE FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 99. EUROPE FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY SEROTONIN AND NOREPINEPHRINE REUPTAKE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 100. EUROPE FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY TRICYCLIC ANTIDEPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 101. EUROPE FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 102. EUROPE FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 103. EUROPE FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 104. MIDDLE EAST FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 105. MIDDLE EAST FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 106. MIDDLE EAST FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY ANTICONVULSANTS, 2018-2032 (USD MILLION)
  • TABLE 107. MIDDLE EAST FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 108. MIDDLE EAST FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY SEROTONIN AND NOREPINEPHRINE REUPTAKE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 109. MIDDLE EAST FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY TRICYCLIC ANTIDEPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 110. MIDDLE EAST FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 111. MIDDLE EAST FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 112. MIDDLE EAST FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 113. AFRICA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 114. AFRICA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 115. AFRICA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY ANTICONVULSANTS, 2018-2032 (USD MILLION)
  • TABLE 116. AFRICA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 117. AFRICA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY SEROTONIN AND NOREPINEPHRINE REUPTAKE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 118. AFRICA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY TRICYCLIC ANTIDEPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 119. AFRICA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 120. AFRICA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 121. AFRICA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 123. ASEAN FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 124. ASEAN FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 125. ASEAN FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY ANTICONVULSANTS, 2018-2032 (USD MILLION)
  • TABLE 126. ASEAN FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 127. ASEAN FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY SEROTONIN AND NOREPINEPHRINE REUPTAKE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 128. ASEAN FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY TRICYCLIC ANTIDEPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 129. ASEAN FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 130. ASEAN FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 131. ASEAN FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 132. GCC FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 133. GCC FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 134. GCC FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY ANTICONVULSANTS, 2018-2032 (USD MILLION)
  • TABLE 135. GCC FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 136. GCC FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY SEROTONIN AND NOREPINEPHRINE REUPTAKE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 137. GCC FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY TRICYCLIC ANTIDEPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 138. GCC FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 139. GCC FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 140. GCC FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 141. EUROPEAN UNION FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 142. EUROPEAN UNION FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 143. EUROPEAN UNION FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY ANTICONVULSANTS, 2018-2032 (USD MILLION)
  • TABLE 144. EUROPEAN UNION FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 145. EUROPEAN UNION FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY SEROTONIN AND NOREPINEPHRINE REUPTAKE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 146. EUROPEAN UNION FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY TRICYCLIC ANTIDEPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 147. EUROPEAN UNION FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 148. EUROPEAN UNION FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 149. EUROPEAN UNION FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 150. BRICS FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 151. BRICS FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 152. BRICS FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY ANTICONVULSANTS, 2018-2032 (USD MILLION)
  • TABLE 153. BRICS FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 154. BRICS FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY SEROTONIN AND NOREPINEPHRINE REUPTAKE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 155. BRICS FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY TRICYCLIC ANTIDEPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 156. BRICS FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 157. BRICS FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 158. BRICS FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 159. G7 FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 160. G7 FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 161. G7 FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY ANTICONVULSANTS, 2018-2032 (USD MILLION)
  • TABLE 162. G7 FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 163. G7 FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY SEROTONIN AND NOREPINEPHRINE REUPTAKE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 164. G7 FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY TRICYCLIC ANTIDEPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 165. G7 FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 166. G7 FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 167. G7 FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 168. NATO FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 169. NATO FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 170. NATO FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY ANTICONVULSANTS, 2018-2032 (USD MILLION)
  • TABLE 171. NATO FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 172. NATO FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY SEROTONIN AND NOREPINEPHRINE REUPTAKE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 173. NATO FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY TRICYCLIC ANTIDEPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 174. NATO FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 175. NATO FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 176. NATO FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 177. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 178. UNITED STATES FIBROMYALGIA THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 179. UNITED STATES FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 180. UNITED STATES FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY ANTICONVULSANTS, 2018-2032 (USD MILLION)
  • TABLE 181. UNITED STATES FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 182. UNITED STATES FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY SEROTONIN AND NOREPINEPHRINE REUPTAKE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 183. UNITED STATES FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY TRICYCLIC ANTIDEPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 184. UNITED STATES FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 185. UNITED STATES FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 186. UNITED STATES FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 187. CANADA FIBROMYALGIA THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 188. CANADA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 189. CANADA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY ANTICONVULSANTS, 2018-2032 (USD MILLION)
  • TABLE 190. CANADA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 191. CANADA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY SEROTONIN AND NOREPINEPHRINE REUPTAKE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 192. CANADA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY TRICYCLIC ANTIDEPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 193. CANADA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 194. CANADA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 195. CANADA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 196. MEXICO FIBROMYALGIA THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 197. MEXICO FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 198. MEXICO FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY ANTICONVULSANTS, 2018-2032 (USD MILLION)
  • TABLE 199. MEXICO FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 200. MEXICO FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY SEROTONIN AND NOREPINEPHRINE REUPTAKE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 201. MEXICO FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY TRICYCLIC ANTIDEPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 202. MEXICO FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 203. MEXICO FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 204. MEXICO FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 205. BRAZIL FIBROMYALGIA THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 206. BRAZIL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 207. BRAZIL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY ANTICONVULSANTS, 2018-2032 (USD MILLION)
  • TABLE 208. BRAZIL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 209. BRAZIL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY SEROTONIN AND NOREPINEPHRINE REUPTAKE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 210. BRAZIL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY TRICYCLIC ANTIDEPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 211. BRAZIL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 212. BRAZIL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 213. BRAZIL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 214. UNITED KINGDOM FIBROMYALGIA THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 215. UNITED KINGDOM FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 216. UNITED KINGDOM FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY ANTICONVULSANTS, 2018-2032 (USD MILLION)
  • TABLE 217. UNITED KINGDOM FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 218. UNITED KINGDOM FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY SEROTONIN AND NOREPINEPHRINE REUPTAKE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 219. UNITED KINGDOM FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY TRICYCLIC ANTIDEPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 220. UNITED KINGDOM FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 221. UNITED KINGDOM FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 222. UNITED KINGDOM FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 223. GERMANY FIBROMYALGIA THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 224. GERMANY FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 225. GERMANY FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY ANTICONVULSANTS, 2018-2032 (USD MILLION)
  • TABLE 226. GERMANY FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 227. GERMANY FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY SEROTONIN AND NOREPINEPHRINE REUPTAKE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 228. GERMANY FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY TRICYCLIC ANTIDEPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 229. GERMANY FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 230. GERMANY FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 231. GERMANY FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 232. FRANCE FIBROMYALGIA THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 233. FRANCE FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 234. FRANCE FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY ANTICONVULSANTS, 2018-2032 (USD MILLION)
  • TABLE 235. FRANCE FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 236. FRANCE FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY SEROTONIN AND NOREPINEPHRINE REUPTAKE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 237. FRANCE FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY TRICYCLIC ANTIDEPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 238. FRANCE FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 239. FRANCE FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 240. FRANCE FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 241. RUSSIA FIBROMYALGIA THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 242. RUSSIA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 243. RUSSIA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY ANTICONVULSANTS, 2018-2032 (USD MILLION)
  • TABLE 244. RUSSIA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 245. RUSSIA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY SEROTONIN AND NOREPINEPHRINE REUPTAKE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 246. RUSSIA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY TRICYCLIC ANTIDEPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 247. RUSSIA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 248. RUSSIA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 249. RUSSIA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 250. ITALY FIBROMYALGIA THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 251. ITALY FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 252. ITALY FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY ANTICONVULSANTS, 2018-2032 (USD MILLION)
  • TABLE 253. ITALY FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 254. ITALY FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY SEROTONIN AND NOREPINEPHRINE REUPTAKE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 255. ITALY FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY TRICYCLIC ANTIDEPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 256. ITALY FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 257. ITALY FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 258. ITALY FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 259. SPAIN FIBROMYALGIA THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 260. SPAIN FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 261. SPAIN FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY ANTICONVULSANTS, 2018-2032 (USD MILLION)
  • TABLE 262. SPAIN FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 263. SPAIN FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY SEROTONIN AND NOREPINEPHRINE REUPTAKE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 264. SPAIN FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY TRICYCLIC ANTIDEPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 265. SPAIN FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 266. SPAIN FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 267. SPAIN FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 268. CHINA FIBROMYALGIA THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 269. CHINA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 270. CHINA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY ANTICONVULSANTS, 2018-2032 (USD MILLION)
  • TABLE 271. CHINA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 272. CHINA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY SEROTONIN AND NOREPINEPHRINE REUPTAKE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 273. CHINA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY TRICYCLIC ANTIDEPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 274. CHINA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 275. CHINA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 276. CHINA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 277. INDIA FIBROMYALGIA THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 278. INDIA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 279. INDIA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY ANTICONVULSANTS, 2018-2032 (USD MILLION)
  • TABLE 280. INDIA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 281. INDIA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY SEROTONIN AND NOREPINEPHRINE REUPTAKE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 282. INDIA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY TRICYCLIC ANTIDEPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 283. INDIA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 284. INDIA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 285. INDIA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 286. JAPAN FIBROMYALGIA THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 287. JAPAN FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 288. JAPAN FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY ANTICONVULSANTS, 2018-2032 (USD MILLION)
  • TABLE 289. JAPAN FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 290. JAPAN FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY SEROTONIN AND NOREPINEPHRINE REUPTAKE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 291. JAPAN FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY TRICYCLIC ANTIDEPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 292. JAPAN FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 293. JAPAN FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 294. JAPAN FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 295. AUSTRALIA FIBROMYALGIA THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 296. AUSTRALIA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 297. AUSTRALIA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY ANTICONVULSANTS, 2018-2032 (USD MILLION)
  • TABLE 298. AUSTRALIA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 299. AUSTRALIA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY SEROTONIN AND NOREPINEPHRINE REUPTAKE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 300. AUSTRALIA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY TRICYCLIC ANTIDEPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 301. AUSTRALIA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 302. AUSTRALIA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 303. AUSTRALIA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 304. SOUTH KOREA FIBROMYALGIA THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 305. SOUTH KOREA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 306. SOUTH KOREA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY ANTICONVULSANTS, 2018-2032 (USD MILLION)
  • TABLE 307. SOUTH KOREA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 308. SOUTH KOREA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY SEROTONIN AND NOREPINEPHRINE REUPTAKE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 309. SOUTH KOREA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY TRICYCLIC ANTIDEPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 310. SOUTH KOREA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 311. SOUTH KOREA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 312. SOUTH KOREA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 313. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2025
  • TABLE 314. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025